When do biologic drug patents expire and when will biosimilars launch?

US Patent 10,300,121: What Do the Claims Actually Cover, and How Crowded Is the US Landscape?

US Patent 10,300,121 is directed to a combination cancer therapeutic method that couples:

thermotherapy using systemically administered tumor-antibody-coated nanoparticles with a thermosensitive polymer coating, heated at the tumor site to damage membranes and release antigen in vivo; with
immunotherapy that includes systemic administration of patient NK cells and/or dendritic cells pre-sensitized in vitro to the tumor and additional nanoparticle-conjugated immune modulators, including VLP and checkpoint inhibitors / ROCK inhibitors / Wnt inhibitors (claim set 1-4) in various schedules (claims 5, 7) and variants (claims 6, 8-15, 16).

The claim language is broad at the method-combination level, but it is also specific at the formulation and modulation level, which creates a landscape with many partial overlaps (nanoparticle thermo-release, antibody-targeted NPs, ultrasound/thermoacoustic/photoacoustic imaging, and immune checkpoint modulation), yet fewer clean end-to-end combinations matching the exact claim structure.

1) Claim Scope: What Is Being Claimed in US 10,300,121?

What the independent claim (claim 1) requires

Claim 1 requires all of the following elements in a single therapeutic method:

Patient and tumor context
Administer the combination to a patient with a tumor.
Thermotherapy component
- Systemic administration of a plurality of tumor-antibody-coated nanoparticles
- Nanoparticles are coated with a thermosensitive polymer
- Heat at the tumor site using an energy source so as to:
  - damage tumor cell membranes
  - release antigenic material in vivo
  - activate and stimulate an immunogenic response of the patient at the tumor site
Immunotherapy component
- Systemically administer the patient’s NK cells/dendritic cells that are pre-sensitized in vitro to the tumor
- Administer tumor-antibody-coated nanoparticles conjugated with:
  - viral-like particles (VLP)
- And simultaneously administer tumor-antibody-coated nanoparticles conjugated with at least one of:
  - checkpoint inhibitors (claim 2 narrows candidates)
  - Rock inhibitors (claim 3 narrows candidates)
  - Wnt inhibitors (claim 4 narrows candidates)
- These are positioned to:
  - prevent proliferation of tumor/metastatic cells
  - prevent tumor/metastatic cells from being “disguised” from T-lymphocytes and/or NK cells

This is a structured combination claim, not a composition claim. It is written to capture a protocol that uses antibody-targeted thermo-releasing NPs plus pre-sensitized immune effectors plus NP-conjugated immune and pathway modulators, delivered in a coordinated manner.

Key dependent claim expansions

Dependent claims add specific implementations or additional sub-steps:

Claim 2 (checkpoint inhibitors list): PD-1, PD-L1, CTLA-4, “Jagged 1 inhibitor 15D11”
Claim 3 (ROCK inhibitors list): Fasudil, exoenzyme, Y-27632, Botox
(claim ties them to reducing inflammation/cytokine storm and preventing autoimmunity)
Claim 4 (Wnt inhibitors list): niclosamide, ivermectin
Claim 5 (annual/repeating regimen + additional polymer materials):
- repeating administration once or twice a year
- conjugated with VLP and with checkpoint/ROCK/Wnt inhibitors
- “thereby reducing an autoimmune reaction”
- further administering NPs conjugated with polylactic acid (PLA) or polyglycolic acid (PGA)
Claim 6 (light-pulse frequency and additional drug): light pulse 20-60 Hz for a medication
Claims 9 and 12 (light/photoacoustic imaging and early-stage tumors):
- claim 9 repeats light pulse 20-60 Hz
- claim 12 adds precision nanoparticle assisted thermotherapy and photoacoustic imaging early in a tumor size 1-2 mm
Claim 10 (thermoacoustic unit + closed-loop temperature control + 37°C to 41-43°C + local release):
- thermoacoustic heating with processor control
- closed circuit once NPs attach
- controllably increase to 41-43°C
- melt thermosensitive polymer coating
- release an attached medication or gene locally
Claim 13 (toxins): snake venom, scorpion venom, bee venom
Claim 14 (cell penetrating peptides): CPP or ACPP
Claim 15 (post-therapy ex vivo blood temperature + dielectrophoresis sorting + reinfusion + immunosuppression):
- heat blood cells up to 60°C to kill immune cells containing nanoparticles
- dielectrophoresis to characterize/remove live/dead T-cells, killer cells, tumor cells
- reinfuse treated blood and simultaneously administer immunosuppressive agents to reduce autoimmune response
Claim 16 (extra imaging requirement and early tumor size): adds photoacoustic image step + tumor size 1-2 mm

“It’s a protocol” structure, which affects infringement risk

Because the claim is a method requiring multiple administered elements, infringement typically requires evidence that an accused regimen performs:

antibody-targeted thermosensitive nanoparticle thermotherapy with membrane damage and antigen release, and
in vitro pre-sensitized NK/dendritic cells administration, and
NP-conjugated VLP plus NP-conjugated checkpoint/ROCK/Wnt inhibitors simultaneously (as written).

This creates a landscape where many technologies may be individually familiar, but the combination is the enforcement target.

2) Critical Reading: Ambiguities and Claim-Strength Inflection Points

Ambiguity cluster A: “Thermotherapy” and “energy source”

Claim 1 requires an energy source at the site but does not limit the energy modality in the independent claim. Dependent claim 10 narrows to thermoacoustic units and closed-loop thermal control.

Impact: if prior art uses ultrasound, focused ultrasound, photothermal, or microwave heating to melt thermosensitive coatings and induce immunogenicity, it can map broadly to the independent claim element without needing thermoacoustic specifics.

Ambiguity cluster B: “tumor-antibody-coated nanoparticles”

The independent claim requires “tumor-antibody-coated nanoparticles” but does not specify:

nanoparticle material (lipid, polymeric, silica, metal)
antibody type (target antigens)
whether nanoparticles are also drug carriers vs purely antigen-release/thermal triggers

Impact: prior art with antibody-targeted NPs for tumor localization can map the “coated with antibody” element even if the polymer composition differs.

Ambiguity cluster C: “VLP” conjugation

The claims require nanoparticles conjugated with viral-like particles. Prior art has many examples of VLP-based vaccines, but fewer on VLP tethered to tumor-antibody-coated, thermotherapy-associated nanoparticles in combination with pre-sensitized NK/dendritic cells.

Impact: this becomes a likely differentiator, unless prior art includes immune-activating nanoparticles with VLP or VLP mimetics.

Ambiguity cluster D: “Rock inhibitors” and nonstandard entries

Claim 3 lists “Fasudil, exoenzyme, Y27632, Botox.”
Fasudil and Y-27632 are known ROCK-pathway inhibitors; the inclusion of “Botox” and “exoenzyme” is a functional fit argument. Prior art mappings may be debated on whether the claimed items meet “Rock inhibitor” role in the prior art.

Impact: if prosecution history construed these terms broadly, landscape mapping expands; if construed narrowly, certain prior art may fail.

Ambiguity cluster E: immunotherapy scheduling “simultaneously”

Claim 1 states nanoparticles conjugated with checkpoint/ROCK/Wnt inhibitors are administered while simultaneously administering nanoparticles conjugated with VLP.

Impact: a protocol that administers checkpoint agents on a different day may avoid this “simultaneously” limitation depending on claim construction and evidence of co-administration timing.

3) Patent Landscape: Where Prior Art Likely Crowds the Claim Elements

Landscape map by claim element

Below is a structured map of the element families embedded in US 10,300,121 and the principal prior-art “vectors” they typically come from.

Claim element in US 10,300,121	Typical prior-art category	What it tends to overlap
Antibody-targeted nanoparticles	Targeted nanocarriers for oncology	“tumor-antibody-coated”
Thermosensitive polymer coating	Heat-responsive nanocarriers	“thermosensitive polymer”
Heating at tumor site to disrupt membranes and release antigen	Thermally induced tumor immunogenicity	“damage membranes” and immune activation
Energy delivery control (thermoacoustic/photoacoustic)	Ultrasound/thermoacoustic/photoacoustic theranostics	Dependent claim 10 and imaging claims
Pre-sensitized NK cells and/or dendritic cells	Cellular immunotherapy protocols	“NK/dendritic cells pre-sensitized in vitro”
VLP immune stimulators	VLP vaccine platforms	“NP conjugated with VLP” (harder overlap)
Checkpoint inhibitors (PD-1/PD-L1/CTLA-4, etc.)	Immune checkpoint therapy	Claim 2 candidates
ROCK inhibitors	Pathway-targeted inflammation control	Claim 3 candidates (partial mapping)
Wnt inhibitors (niclosamide, ivermectin)	Wnt pathway modulation	Claim 4 candidates (partial mapping)
Ex vivo blood processing and re-infusion	Cellular immune modulation + ex vivo treatments	Claim 15 uniqueness

What this means for novelty and obviousness risk

Lowest-risk area for novelty: antibody-targeted thermosensitive nanoparticles + heat-triggered immunogenicity is a well-trodden concept in nanoimmunotherapy. The independent claim’s thermotherapy language is broad enough to capture many existing thermo-responsive oncology platforms.
Moderate-risk area: simultaneous NP-conjugated checkpoint inhibitors with VLP is more specific, but checkpoint inhibition is pervasive and may be combined with a wide variety of delivery systems.
Highest-risk area for novelty: “pre-sensitized NK cells/dendritic cells in vitro” can be found in many adoptive immunotherapy workflows; if these are combined with a thermal antigen-release platform in prior literature, mapping can proceed without needing VLP.
Highest differentiator likely: the requirement that the nanoparticles are conjugated with VLP plus checkpoint/ROCK/Wnt inhibitors and that the method also uses in vitro pre-sensitized NK/dendritic cell infusion. This is a multi-factor combination that few prior art sources hit at once.

4) Claim-by-Claim Enforcement Levers

Claims 1-4 (core combination)

Claim 1 anchors the combination and is the likely primary litigation target.
Claims 2-4 provide enumerated payloads and reduce argument space around what qualifies as “checkpoint inhibitors / ROCK inhibitors / Wnt inhibitors.”

Enforcement implication: if a competitor uses different inhibitors than the listed ones, they may escape dependent-claim constraints but still be exposed under claim 1 depending on whether claim 1 reads broadly to “at least one of checkpoint inhibitors, Rock inhibitors, or Wnt inhibitors” without limiting to listed members. In US practice, dependent claim lists can influence construction and prosecution history.

Claims 5, 6, 7 (schedule and dosing pattern)

Claim 5: repeating once or twice a year and adding PLA/PGA conjugation
Claim 6: light pulse frequency 20-60 Hz to decrease proliferation
Claim 7: booster immunotherapy at intervals to reduce recurrences

Enforcement implication: these create narrower “protocol signatures.” If a competitor’s schedule differs, claim 1 remains the fallback.

Claims 10, 12 (hardware and imaging)

Claim 10: thermoacoustic unit, closed-loop temperature maintenance, controlled heating to 41-43°C, melting thermosensitive polymer, local release of attached medication/gene
Claim 12/16: photoacoustic imaging and early-stage tumor size 1-2 mm

Enforcement implication: these are higher-specificity hooks. If accused systems use ultrasound-based thermal ablation or photoacoustic-guided targeting, overlap is more plausible.

Claims 13-15 (payload add-ons and ex vivo immune control)

Claim 13: venom toxins
Claim 14: CPP/ACPP
Claim 15: ex vivo blood heating to 60°C, dielectrophoresis sorting, reinfusion with immunosuppressives

Enforcement implication: these are likely the most differentiated features; if a competitor does not perform ex vivo blood processing or venom/CPP conjugation, those dependents are less relevant.

5) Practical Patent-Strategy Conclusions for Developers and Investors

1) Risk is concentrated in the independent claim’s thermotherapy + adoptive immunotherapy core

The independent claim’s structure is broad enough to be asserted against any regimen that:

uses antibody-targeted thermosensitive nanoparticles heated at the tumor to produce antigen release and immunogenicity, and
administers in vitro pre-sensitized NK/dendritic cells, and
adds NP-conjugated VLP plus NP-conjugated immune/pathway modulators.

This is not a “single technology” claim. It is a multi-component combination claim that can still be implicated if an accused regimen uses a similar build.

2) VLP conjugation and simultaneous inhibitor dosing are likely the hardest to prove but also the hardest to design around

If an accused approach omits VLP conjugation on tumor-targeting nanoparticles, it may avoid key claim language.
If inhibitors are delivered systemically on different timing, it may avoid “simultaneously” limitation in claim 1.

3) Dependent claims create multiple narrow paths, but claim 1 remains the litigation anchor

Even if a competitor avoids one dependent feature (photoacoustic imaging, thermoacoustic unit, toxin payloads, CPP/ACPP, ex vivo blood processing), claim 1 can still capture the protocol if the central elements are present.

4) Technical design-around opportunities likely exist, but the combination is the constraint

From a product architecture standpoint, design-around typically requires altering:

thermotherapy modality or polymer behavior,
antibody targeting structure,
immune effector preparation steps,
VLP conjugation method,
timing of NP-conjugated immune modulators.

Separating these elements in development may reduce risk under a combination claim, but it may also impair clinical performance if those features are synergistic.

Key Takeaways

US 10,300,121 claims a multi-component cancer immunotherapy protocol combining thermosensitive, antibody-targeted nanoparticles heated at the tumor to induce in vivo antigen release with systemic infusion of in vitro pre-sensitized NK/dendritic cells, plus NP-conjugated VLP and NP-conjugated checkpoint/ROCK/Wnt modulators administered simultaneously as written in claim 1.
The thermotherapy and adoptive immunotherapy components map to common nanoimmunotherapy and cellular immunotherapy prior-art vectors, which increases landscape crowding at the element level.
The likely hardest-to-match features across the landscape are the exact combination of VLP conjugation on the same tumor-targeting nanoparticle platform and the simultaneous NP-conjugated checkpoint/ROCK/Wnt inhibitor administration paired with in vitro pre-sensitized NK/dendritic infusion.
Enforcement leverage is greatest where an accused regimen reproduces the claim’s protocol-level integration, not where it merely borrows one technology class.

FAQs

1) Is US 10,300,121 primarily a nanoparticle composition patent or a treatment regimen patent?

It is a method-of-treatment patent. The claims require administration steps and coordinated therapeutic components, including cellular therapy preparation and multiple nanoparticle conjugates.

2) What is the single most specific differentiator in the claim set?

Claim 1’s requirement that the method includes tumor-antibody-coated nanoparticles conjugated with VLP, paired with simultaneous administration of nanoparticles conjugated with checkpoint inhibitors, ROCK inhibitors, and/or Wnt inhibitors, alongside in vitro pre-sensitized NK/dendritic cell infusion.

3) If a competing therapy uses thermosensitive antibody-targeted nanoparticles and checkpoint blockade, does it necessarily infringe claim 1?

Not necessarily. Claim 1 also requires in vitro pre-sensitized NK/dendritic cell administration and NP-conjugated VLP plus the simultaneous NP-conjugated pathway/inhibitor elements as written.

4) Which dependent claims are most “implementation-specific”?

Claims 10, 12/16, and 15. They specify a thermoacoustic control system, photoacoustic imaging for 1-2 mm tumors, and ex vivo blood processing with dielectrophoresis.

5) Does the claim set limit the tumor antibody to a particular biomarker?

Claim 11 states the antibody can be specific for at least one tumor biomarker in the patient’s blood, but claim 1 itself does not enumerate biomarker targets.

References

[1] United States Patent 10,300,121 (claims text as provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	10,300,121	2037-12-24
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	10,300,121	2037-12-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,300,121

Summary for Patent: 10,300,121